A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Part of paid clinical trials in Los Angeles, California.

Sponsor
Jazz Pharmaceuticals
Study ID
NCT07459634
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Extensive-stage Small-cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lurbinectedin — DRUG
    Administered by intravenous (IV) infusion
  • Durvalumab — DRUG
    Administered by intravenous (IV) infusion

Study Details

The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.

Key Dates

Start date
Jun 12, 2026
Status verified
May 2026
Primary completion
Jan 31, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Durvalumab and lurbinectedin treatment arm
    Durvalumab taken in combination with lurbinectedin in participants with ES-SCLC after first line induction therapy with durvalumab and platinum plus etoposide containing regimen.

Primary Outcome Measure

Investigator assessed PFS rate [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Valkyrie Clinical Trials, Inc.Los AngelesCalifornia90067-

Find similar trials in Los Angeles, CA

By research site
Valkyrie Clinical Trials, Inc.· Los Angeles, CA

Related Studies